Tazar

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tazar

What is Tazar? Overview and Identity

Property Description
Active Ingredients Piperacillin Sodium Salt, Tazobactam Sodium Salt
Form Sterile Powder for Solution for Infusion
Pharmacological Class beta-Lactam Antibiotic with beta-Lactamase Inhibitor
General Purpose Treatment of serious bacterial infections
Origin Semisynthetic / Synthetic Combination

What is Tazar and What Type of Medicine is It?

Tazar is a potent, fixed-dose combination product containing the active ingredients Piperacillin and Tazobactam. It is primarily classified as an antiinfective agent belonging to the semisynthetic beta-lactam antibiotic class. This medication is a prescription-only treatment, typically reserved for addressing moderate-to-severe bacterial infections in clinical settings. The combination design makes Tazar structurally and functionally superior to older monotherapies by effectively circumventing bacterial resistance mechanisms.


Key Components and Physical Form

Tazar is composed of the sodium salts of its active ingredients: Piperacillin Sodium Salt and Tazobactam Sodium Salt. This specific formulation is distinguished by its dosage form: a sterile cryodesiccated powder for solution for infusion, classifying it as a parenteral medicine. Piperacillin is derived from earlier penicillin structures, classifying it as semisynthetic, while Tazobactam is a completely synthetic compound. This powder requires reconstitution into a liquid solution immediately prior to administration into a vein via intravenous administration. This preparation method is used for systemic infections that necessitate rapid and complete absorption of the full dose.


How the Combination Achieves its General Purpose

The general purpose of this combination is to provide a broad-spectrum tool capable of reliably eliminating bacteria, including many drug-resistant strains. Piperacillin's role is to act as the primary destroyer, exhibiting bactericidal activity by interfering with the structural integrity of the bacterial cell wall. Tazobactam's critical function is to chemically neutralize the defensive beta-lactamase enzymes produced by resistant bacteria, ensuring the destructive power of Piperacillin is maintained. This mechanism is clinically recognized for its effectiveness in clearing complicated or hospital-acquired infections, serving as a standard treatment option when susceptible bacteria are confirmed.

What side effects are possible with Tazar?

Possible Side Effects and Safety Information

The safety profile of Tazar (Piperacillin/Tazobactam) is officially documented by regulatory agencies and classified according to the specific physiological systems affected and the frequency of occurrence.

Adverse Reactions by Frequency

Adverse events are categorized using standardized frequency terminology:

  • Very Common (ge 1/10): Typically includes diarrhea.
  • Common (ge 1/100 to < 1/10): Includes nausea, vomiting, constipation, headache, insomnia, rash, and pyrexia (fever).
  • Uncommon (ge 1/1,000 to < 1/100): Includes adverse reactions affecting the nervous system, such as convulsions (seizures), and vascular disorders like hypotension.

Serious Adverse Reactions and Systemic Effects

The official labeling highlights rare but serious reactions, including severe hypersensitivity events such as anaphylactic/anaphylactoid reactions and severe cutaneous adverse reactions like Stevens-Johnson Syndrome (SJS) and DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms). Other serious effects include potentially life-threatening conditions like Clostridioides difficile-Associated Diarrhea (CDAD) and Acute Kidney Injury (AKI).

Safety notes specify that effects on the blood and lymphatic system (e.g., leukopenia, neutropenia) may occur, particularly during prolonged therapy. Furthermore, population-specific safety considerations exist, noting that patients with renal impairment are at increased risk for neurological complications and bleeding manifestations. The co-administration with certain other medicines, such as vancomycin, may increase the incidence of nephrotoxicity.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the overdose profile of Tazar by its potential for serious systemic and neurological effects associated with high drug exposure.

Element Official Regulatory Statement
Documented Manifestations Neuromuscular excitability, Seizures (Convulsions), Nausea, Vomiting, and Diarrhea.
Physiological Systems Affected Central Nervous System (CNS), Musculoskeletal (Rhabdomyolysis), Renal, Hematopoietic, and Metabolic (Hypokalemia).
Population-Specific Risk Patients with impaired renal function are at a greater risk of CNS toxicity and seizures, as drug clearance is reduced.

In the event of suspected overdosage, the mandatory regulatory guidance is to contact a poison control center or emergency room at once. Immediate medical attention is required for the suspected overexposure or the presentation of life-threatening syndromes. Severe outcomes documented in regulatory sources include Rhabdomyolysis and serious hematological effects like leukopenia.

The documented intervention for Tazar overdose is symptomatic and supportive treatment, as official information confirms that no specific antidote is known. Hemodialysis is listed as a procedural option that can be utilized to remove the active ingredients from the circulation. Close monitoring is required for patients exhibiting signs of neurological or severe systemic toxicity.

Therapeutic Uses of Tazar

What Tazar Treats: Main Uses and Benefits

Tazar (Piperacillin/Tazobactam) is commonly used to help manage moderate-to-severe bacterial infections in clinical settings where patients may require significant supportive care. The primary therapeutic role is to support the patient’s body in clearing the infection and addressing systemic imbalance, which may assist in easing the overall symptom load associated with acute, serious manifestations. This use is well-established across multiple domains.

Treating Severe Infections in the Abdomen and Deep Tissue

This medication is applied in addressing complicated intra-abdominal infections like peritonitis, severe pneumonias (especially those hospital-acquired), and deep-seated complicated skin and soft tissue infections such as diabetic foot infections. Tazar is also applied when appropriate for bacteraemia (bacteria in the blood) and is often used during phases when symptoms become more noticeable in patients with febrile neutropenia. This intervention contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable, supporting general well-being during symptomatic phases.

Quick Fact: Relief for Severe Systemic Fever

Tazar is commonly used to help with managing symptoms related to systemic imbalance, such as intense, persistent fever that may signal a significant systemic bacterial infection, particularly in high-risk scenarios like febrile neutropenia.

Regulatory References

  1. NIH DailyMed label information

Eligibility and Restrictions for Use

Contraindications (Who Must Not Use Tazar)

Tazar (Piperacillin/Tazobactam) is absolutely contraindicated for use in patients who have a documented history of severe allergic reactions (hypersensitivity) to any penicillin-class antibiotic or to other related beta-lactam agents, such as cephalosporins. This regulatory exclusion is based on the potential for serious or life-threatening reactions.


Age and Developmental Eligibility

The medicine's use is established for adults, adolescents, and children 2 months of age and older for their approved indications. However, safety and efficacy have not been established for infants younger than 2 months. Use in older adults is permitted, though dose selection must be approached with caution due to the greater frequency of decreased kidney function.


Conditional Use and Restrictions

Eligibility for Tazar is conditional on certain factors. Patients with renal impairment are restricted and require mandatory dose adjustment when their kidney function, measured by creatinine clearance, is below 40 mL/min. For pregnancy and breastfeeding, Tazar should only be used if clearly indicated, as limited data means the expected benefit must outweigh potential risks to the fetus or child. Caution is also required for patients with specific comorbidities, including seizure disorders and conditions sensitive to the medicine's sodium content.

What should I know about interactions with other medicines?

Tazar (tazarotene) is a topical retinoid that can interact with other topical products and certain systemic medications, primarily by increasing the risk of skin irritation or photosensitivity (increased sensitivity to sunlight).

Products to Avoid or Use with Caution

It is important to inform your healthcare provider about all medicines, over-the-counter products, and cosmetics you use. Due to the potential for increased irritation, exercise caution with topical products that have a strong drying effect or contain high amounts of alcohol, astringents, spices, or lime.

  • Other Topical Irritants: Avoid using Tazar simultaneously with other topical medications that may irritate the skin, such as:
    • Medicated or abrasive soaps and cleansers
    • Preparations containing sulfur, resorcinol, or salicylic acid
    • Benzoyl peroxide (if used, discuss applying it at a different time of day, e.g., Tazar in the evening, benzoyl peroxide in the morning)
  • Cosmetic Procedures: Temporary interruption of Tazar treatment may be necessary after certain cosmetic procedures, such as hair removal, chemical peels, or electrolysis.

Systemic Drug Interactions

Tazar can increase your skin's sensitivity to sunlight (photosensitivity). This effect may be amplified when used with other photosensitizing drugs. Your doctor may advise increased sun protection or a change in medication if you are taking:

  • Certain Antibiotics: Tetracyclines (e.g., doxycycline) or fluoroquinolones (e.g., ciprofloxacin)
  • Diuretics: Thiazides (e.g., hydrochlorothiazide)
  • Other Drugs: Phenothiazines, sulfonamides, or NSAIDs (non-steroidal anti-inflammatory drugs) such as naproxen or ibuprofen.

Mechanism of Action

The mechanism of Tazar involves the simultaneous action of two molecules that execute a dual function: disruption of the bacterial structure and inactivation of microbial beta-lactamase enzymes. This coordinated activity results in a synergistic bactericidal effect.


Functional Rescue and Defense Neutralization

This domain covers Tazobactam's role, focusing on its specific target: bacterial beta-lactamase enzymes. Tazobactam acts as a suicide inhibitor, irreversibly binding to and deactivating these enzymes. This step results in the prevention of Piperacillin hydrolysis, allowing the intact molecule to reach its intended targets within the bacterial cell.


Covalent Inhibition of Bacterial Cell Wall Synthesis

This core domain involves Piperacillin targeting the Penicillin-Binding Proteins (PBPs), which are bacterial enzymes vital for cell wall construction. Piperacillin forms a stable, covalent bond with the PBPs, halting the process of peptidoglycan cross-linking. This structural inhibition cascade leads to the activation of bacterial autolytic enzymes, which mediate the collapse and rupture (lysis) of the cell, resulting in bacterial cell lysis (bactericidal activity).


Mechanistic Constraints and Target Affinity

This domain addresses the biological boundaries of Tazar's efficacy. The mechanism is inherently constrained where resistance is mediated by enzyme types that Tazobactam cannot inhibit, such as Metallo-beta-Lactamases (MBLs), or by bacteria that express altered PBP targets with significantly reduced affinity for Piperacillin. This results in the functional failure of the mechanism against these specific strains.

Dosage and Administration Information

How to Use Tazarotene (Tazar/Tazorac) — Administration Guidelines

The use of tazarotene, the active ingredient in Tazar, is defined to support appropriate topical application and dosing. Tazarotene is available as a cream, gel, foam, and lotion in strengths such as 0.05% and 0.1%.


Administration Protocol

Procedural Element Instruction
Route & Frequency Topical use only; applied once daily in the evening or at bedtime.
Application Amount Apply a thin layer to the affected area. For facial application, a pea-sized amount is generally specified.
Skin Condition Must be applied to clean, fully dry skin.
Coverage The treated area must not be covered with occlusive dressings (bandages or wraps).

Procedural Steps

The sequence of administration is standardized across formulations:

  1. Preparation: Gently wash the skin with a mild cleanser and ensure the area is completely dry before application. (Note: Shake the can if using the foam formulation).
  2. Application: Apply the prescribed amount (cream, gel, or lotion) only to the affected skin, gently massaging it in until it disappears.
  3. Post-Application: Wash hands thoroughly immediately after use, unless the hands are the area being treated.

Specific Limitations

Administration is restricted to no more than 20% of the total body surface area when treating psoriasis with the gel formulation. Tazarotene is approved for use in pediatric patients for certain indications, generally those 12 years of age and older. If a dose is missed, patients should apply it as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tazar

Evidence for Use in Complicated Intra-Abdominal Infections

Research has explored the profile of Tazar in patients with serious deep abdominal infections. The evidence primarily comes from short-term Randomized Controlled Trials (RCTs) and comprehensive meta-analyses that compared Tazar-containing regimens to other established antibiotic options. The studies monitored outcomes related to clinical success and microbiological eradication of the susceptible bacteria. Findings generally describe patterns of measured clinical and bacterial clearance in the study populations, including both adults and pediatric patients (aged two and older).

Evidence for Use in Nosocomial (Hospital-Acquired) Pneumonia

The research for Tazar in severe lung infections acquired in hospitals, such as Hospital-Acquired Pneumonia (HAP), mainly consists of RCTs. These studies examined Tazar in patients, including many critically ill adults. The main outcomes monitored included measurements of clinical cure and survival status. The overall data describe patterns observed when Tazar was evaluated against other standard regimens studied for these specific infections. Notably, ongoing research explores whether different administration strategies, such as prolonged infusion, may influence the measured outcomes, particularly in critically ill patients who may clear the drug quickly.

Evidence for Use in Febrile Neutropenia

Tazar was studied for use as an empirical therapy—a treatment started when infection is suspected—in high-risk patients who have a fever along with a severely low white blood cell count (neutropenia). The trials explored outcomes in both adults and children. Findings from the studies indicate that patterns of fever resolution were monitored in Tazar combination regimens, and the reported rates were within the range of those seen with other established empirical treatments. The evidence for Tazar used as a monotherapy (by itself) in this scenario is limited.

What is Still Uncertain About Tazar Research

Despite the existence of several large-scale studies, there are still several aspects of Tazar's use where certainty remains low or research is still needed. The follow-up durations were limited in many pivotal trials, meaning research provides limited insight into the long-term impact on infection recurrence or sustained health status. Furthermore, data for certain groups remain insufficient, such as neonates (newborns), and research is ongoing regarding the optimal dosing strategy for patients with variable kidney function.

Key Studies & References Piperacillin/Tazobactam (Zosyn) Official Prescribing Information - DailyMed

Frequently Asked Questions (FAQ)

Common questions about Tazar (FAQ)


Q: Is Tazar available over the counter or only with a prescription?

A: Tazar (Piperacillin/Tazobactam) is a prescription-only medication. According to official product information, it is typically reserved for addressing moderate-to-severe bacterial infections in a clinical or hospital setting.


Q: Are there any dietary restrictions while taking Tazar?

A: Since Tazar is an intravenous (IV) medication, official labeling does not list any specific dietary restrictions or food interactions. This form of the medicine is generally not affected by food intake in the way some oral medications are.


Q: Can Tazar interact with alcohol?

A: Regulatory documents do not list a direct interaction between Tazar (Piperacillin/Tazobactam) and alcohol. However, it is advisable to discuss alcohol use with a healthcare professional during treatment for a serious infection.


Q: Does Tazar affect blood pressure readings?

A: Yes, Tazar can potentially affect blood pressure. The official safety information notes that hypotension (low blood pressure) is an uncommon adverse reaction, which could impact blood pressure measurements while taking the medicine.


Q: Can Tazar affect my mood or cause anxiety?

A: Official reports indicate some effects on the nervous system. Insomnia (difficulty sleeping) is listed as a common side effect. More serious central nervous system issues, such as convulsions (seizures) and hallucinations, have been listed as uncommon or rare effects.


Q: Does Tazar have a potential for abuse or dependence?

A: No. Tazar is an antibiotic and is not listed as a controlled substance by regulatory authorities. The official labeling contains no reports of abuse or dependence.


Q: Does Tazar affect the results of common blood tests?

A: Official information indicates that Tazar, like other penicillin-class antibiotics, can cause interference in some tests for glucose (sugar) in the urine. This may potentially lead to a misleading test result.


Q: Can Tazar be crushed or split if someone has trouble swallowing?

A: No. Tazar is supplied as a sterile powder that must be reconstituted (mixed) into a solution for intravenous infusion. It is not designed to be taken by mouth, crushed, or split.


Q: What does the dosage strength of Tazar refer to?

A: The dosage strength refers to the combined total amount of both active ingredients: Piperacillin and Tazobactam. For example, a 4.5g strength contains a specific ratio of Piperacillin to Tazobactam.


Q: How should Tazar be stored at home?

A: The unopened Tazar powder is intended to be stored at a controlled room temperature (20 C to 25 C). Once the powder has been prepared into a solution for use (reconstituted), administration protocols generally require storage in a clinical setting.


Q: Is it true that Tazar is a relatively new drug?

A: The combination product containing Piperacillin and Tazobactam is an established medicine. It was first approved by the U.S. Food and Drug Administration (FDA) in 1993.


Q: Can Tazar be used by pregnant or breastfeeding individuals?

A: Official product information states that Tazar should only be used during pregnancy or breastfeeding if the benefit is considered to outweigh the potential risks to the fetus or child. This caution is due to limited data and the fact that the drug crosses the placenta.


Q: What if I experience stomach upset every time I take Tazar?

A: Official safety data indicates that diarrhea is a very common side effect, while nausea and vomiting are common. These are expected to be reported to the healthcare professional managing the treatment.


Q: Can I take Tazar if I have a pre-existing heart condition?

A: Official warnings advise caution for patients with heart conditions or high blood pressure. This is due to the medicine's sodium content (salt), which can be a concern for individuals sensitive to salt intake.


Q: Are there any long-term risks associated with Tazar use?

A: When Tazar is used for prolonged therapy, serious adverse effects on the blood cell counts (hematological effects) and potential kidney damage (nephrotoxicity) may occur. These risks are typically monitored closely by health professionals.


Q: Can Tazar affect my sleep pattern?

A: Yes, Tazar is known to affect sleep. Insomnia (difficulty falling or staying asleep) is listed in official documentation as a common side effect.


Q: Why does the packaging for Tazar include a specific warning?

A: Regulatory labeling includes strong warnings to highlight the risk of rare but serious adverse events. These can include life-threatening allergic reactions, severe skin conditions, and potential harm to the kidneys.


Q: Are there any reported cases of Tazar causing liver problems?

A: Official information notes that mild-to-moderate elevations in liver enzymes have been observed in some patients. Rare instances of idiosyncratic liver injury (a type of unpredictable reaction) have also been reported.


Q: Is Tazar a good treatment option for initial diagnosis?

A: Tazar may be used as presumptive therapy (initial treatment when a bacterial infection is suspected but the exact cause is not yet known). This use is due to its broad spectrum of activity against many types of bacteria.


Q: Can Tazar be prescribed by a general practitioner?

A: Tazar is generally used for moderate-to-severe infections and is often administered in a clinical setting under specialist advice. While any licensed prescriber may authorize it, its use is typically reserved for hospital or complex care environments.


Q: Does Tazar cause drowsiness or affect my ability to drive?

A: Official post-marketing reports list drowsiness as a rare side effect of Tazar. If you experience drowsiness, it should be brought to the attention of a healthcare professional.

How should Tazar be stored and disposed of?

How to Store and Dispose of Tazar (Piperacillin/Tazobactam)

Official regulatory guidelines require the unopened Tazar powder for injection to be stored at Controlled Room Temperature (20 C to 25 C). The reconstituted solution is subject to strict stability limits that must be observed to maintain potency.

Stability and Handling

Condition Stability Period
Room Temperature (20 C to 25 C) Discard after 24 hours
Refrigerated (2 C to 8 C) Discard after 48 hours

The reconstituted solution must not be frozen. It must not be mixed with incompatible substances such as sodium bicarbonate or blood products. All unused or expired product must be disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tazar found in:

A-Z Index: